Allogeneic Hematopoietic Cell Transplantation clinical trials at UC Irvine
2 research studies open to eligible people
Prospect Eval of Efficacy of CMV-TCIP Direct Letermovir Prophylax After Allogen Hemato Cell Transpla
open to eligible people ages 18 years and up
This is a phase 2, prospective cohort clinical trial evaluating the utilization of CMV T Cell Immunity Panel (CMV-TCIP) assay to guide the duration of primary CMV prophylaxis in CMV-seropositive recipients of allogeneic stem cell transplant or recipients receiving a stem cell graft from a CMV serology positive donor.
Orange, California
Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation
open to eligible people ages 18-70
This is a prospective, single-arm, phase II study. Patients will be treated with an allogeneic stem cell transplantation (AHSCT) using fludarabine, melphalan and total body irradiation (TBI) conditioning with different melphalan and TBI doses based on patient- and disease-related risk.
Orange, California
Our lead scientists for Allogeneic Hematopoietic Cell Transplantation research studies include Stefan Octavian Ciurea Piyanuch Kongtim.
Last updated: